Words by Isabel O’Brien
Austin-based startup Revisto has raised 4m (USD) in seed funding to simplify the pharmaceutical industry’s marketing compliance processes using AI. The funding round was led by LiveOak Ventures, with backing from Eli Lilly, Tau Ventures and Arkin Digital Health, bringing the company’s total funding to 6m (USD).
“This funding validates the transformative potential of Revisto’s AI-driven solution in the pharmaceutical industry,” said Ferry Tamtoro, CEO, Revisto, “and offers early adopters a significant time-to-market edge while saving money and preserving more of their MLR review team’s bandwidth for their central tasks.”
The company’s AI platform is designed to reduce the time it takes for companies to bring marketing materials to market while ensuring they comply with strict regulations.
Revisto’s AI, trained on extensive pharmaceutical data, integrates with existing systems like Veeva Vault PromoMats. By automating manual processes, the technology aims to address what many in the industry see as a persistent bottleneck in the review cycle.
With a team of just over ten employees, Revisto plans to expand and refine its AI capabilities following this latest funding round, focusing on enhancing the platform’s detection and recommendation features.
